Knight Cancer Institute

Cardiff Oncology Reports Third Quarter 2023 Results and Provides Business Update

Retrieved on: 
Thursday, November 2, 2023
Science, Neoplasm, Patient, FDA, Gemcitabine, Progression-free survival, Biomarker, FOLFIRI, Oregon Health & Science University, PLK1, Knight Cancer Institute, Oregon Health and Science University Center for Women's Health, Clinical uses of mesenchymal stem cells, Pfizer, Cancer, OHSU, University of Pittsburgh Medical Center, CRDF, PT, SAN, ORR, University, SOC, Safety, Dicarboxylic acid, Investment, PR, Pharmaceutical industry, Cryptocurrency

"This has been a transformational quarter for Cardiff Oncology.

Key Points: 
  • "This has been a transformational quarter for Cardiff Oncology.
  • Contingent upon the results of CRDF-004, Cardiff Oncology plans to initiate CRDF-005, a Phase 3, randomized trial with registrational intent.
  • As of September 30, 2023, Cardiff Oncology had approximately $81.4 million in cash, cash equivalents, and short-term investments.
  • Cardiff Oncology will host a corresponding conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on November 2, 2023.

Cardiff Oncology Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, including Single-Agent Activity from Onvansertib Monotherapy

Retrieved on: 
Tuesday, September 26, 2023
Dicarboxylic acid, Pancreatic cancer, Carcinoma, IIT, CRDF, Progression-free survival, Serum, Phase II, Neoplasm, Clinical uses of mesenchymal stem cells, Gemcitabine, PT, SOC, Biomarker, PLK1, SCLC, Oregon Health and Science University Center for Women's Health, MD, Standard of care, Patient, SAN, OHSU, Cancer, Knight Cancer Institute, ORR, Oregon Health & Science University, PR, Safety, Pharmaceutical industry, PDAC

In small cell lung cancer, we are encouraged to observe single-agent activity with onvansertib monotherapy in this difficult-to-treat extensive stage refractory setting."

Key Points: 
  • In small cell lung cancer, we are encouraged to observe single-agent activity with onvansertib monotherapy in this difficult-to-treat extensive stage refractory setting."
  • "We will continue to explore onvansertib in the first-line mPDAC investigator-initiated trial at the OHSU Knight Cancer Institute."
  • In cohort 2, patients will receive 10 days of onvansertib monotherapy followed by onvansertib + SoC to identify biomarkers that predict response to onvansertib.
  • Cardiff Oncology will host a corresponding conference call and live webcast at 5:00 p.m. ET/2:00 p.m. PT on September 26, 2023.

AHN Opens New Precision Medicine and Developmental Therapeutics Cancer Clinic at AGH

Retrieved on: 
Thursday, September 7, 2023
Allegheny, Telehealth, University, Cancer Institute, American Board of Internal Medicine, Personalized medicine, Cancer, Development of the human body, Multimedia, Allegheny General Hospital, MS, American Board of Commissioners for Foreign Missions, Oregon Health Plan, Allegheny Health Network, National Cancer Center, Protein, Medical director, AHN, Patient, Physician, Walter Reed National Military Medical Center, Internal medicine, Medicine, Ponce Health Sciences University, Oncology, FDA, Health, Empowerment, Knight Cancer Institute, Disease, Hospital, Pharmaceutical industry, Medical imaging, MD

PITTSBURGH, Sept. 7, 2023 /PRNewswire-PRWeb/ -- The Allegheny Health Network Cancer Institute (AHNCI) announced today that it has established one of the region's first clinics dedicated to precision cancer medicine and has appointed nationally recognized medical oncologist Ariel Lopez-Chavez, MD, MS, to serve as director of the new clinic.

Key Points: 
  • The AHNCI's Precision Medicine and Developmental Therapeutics Clinic focuses on serving adults with metastatic solid tumors, and patients who may need second opinions or are seeking novel treatment options for rare, complex, or advanced-stage cancers.
  • The clinic is based at the AHN Cancer Institute at Allegheny General Hospital in Pittsburgh's North Side and offers both in-person and telemedicine appointments to patients.
  • Because every cancer patient has unique characteristics and preferences, a unique genetic profile, and because cancer is a dynamic, heterogeneous disease, precision therapies are considered the next frontier of cancer treatment.
  • As director of the Precision Medicine and Developmental Therapeutics Clinic, Dr. Lopez-Chavez will lead an innovative program that offers cancer patients access to clinical research trials and novel technologies aimed at maximizing cancer recovery and improving their overall well-being.

Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900

Retrieved on: 
Wednesday, September 6, 2023
KOL, University, Oregon Health & Science University, Platinum, University of Arizona College of Medicine – Tucson, Doctor of Philosophy, University of California, San Diego, Patient, SUNY Downstate Health Sciences University, FACS, Ovarian cancer, Cancer, Knight Cancer Institute, Safety, Pharmaceutical industry, FACOG, MD

Fort Lee, NJ, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced it will host a virtual KOL event to discuss its two clinical-stage drug candidates, NXP800 and NXP900, on Thursday, September 14, 2023 at 10:00am ET.

Key Points: 
  • Fort Lee, NJ, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced it will host a virtual KOL event to discuss its two clinical-stage drug candidates, NXP800 and NXP900, on Thursday, September 14, 2023 at 10:00am ET.
  • To register for the event, please click here .
  • The event will feature Bradley J. Monk, MD, FACS, FACOG (University of Arizona College of Medicine) and Ramez N. Eskander, MD (University of California San Diego) who will discuss the clinical development opportunity for NXP800 in ovarian cancer, and specifically in patients with platinum resistant, ARID1a-mutated ovarian carcinoma, a patient population that is currently being enrolled into an ongoing Phase 1b clinical trial in which the safety and preliminary efficacy of NXP800 is being investigated, and Gordon Mills, MD, PhD (Knight Cancer Institute, Oregon Health & Science University) who will discuss the clinical development opportunities for NXP900 as the Phase 1a dose escalation study is about to commence.
  • A live question and answer session will follow the formal presentations.

Susan G. Komen® Hosts Annual 2023 Oregon and Northwest Washington MORE THAN PINK Walk

Retrieved on: 
Friday, August 18, 2023
Survivor, Pacific Northwest, Friends, Oregon Zoo, Zoo, Research, Development, THAN, Patient, Walking, Breast cancer, Family, Knight Cancer Institute, Caregiver, Disease, Birth control, Oregonian, Northwest (Washington, D.C.)

PORTLAND, Ore., Aug. 18, 2023 /PRNewswire/ -- Susan G. Komen®, the world's leading breast cancer organization, will be hosting the return of the 2023 Oregon and Northwest Washington MORE THAN PINK Walk on Saturday, September 16. The annual Walk will be held for the first time at the Oregon Zoo.  

Key Points: 
  • PORTLAND, Ore., Aug. 18, 2023 /PRNewswire/ -- Susan G. Komen® , the world's leading breast cancer organization, will be hosting the return of the 2023 Oregon and Northwest Washington MORE THAN PINK Walk on Saturday, September 16.
  • The annual Walk will be held for the first time at the Oregon Zoo.
  • Walk participants will include breast cancer survivors, metastatic breast cancer thrivers, co-survivors and supporters of Susan G. Komen.
  • Please contact Deb Song at [email protected] for interviews, live-shots Interviews with event attendees, Komen staff, and honorees can be granted upon request.

Kineta Appoints Internationally-Renowned Clinical Immuno-oncology Experts to its Scientific Advisory Board

Retrieved on: 
Wednesday, March 1, 2023
Netherlands Cancer Institute, Immunotherapy, Cancer, Prostate cancer, DNA, University, Principal, Basic research, SAB, VISTA, Stomach cancer, Associate, Core, Fred Hutchinson Cancer Research Center, Research, University of Washington School of Medicine, Gastrointestinal cancer, Pacific Northwest, United States Department of Defense, National Cancer Institute, Biomarker, LAPS, Knight Cancer Institute, Patient, Esophageal cancer, Trial of the century, IDeA Networks of Biomedical Research Excellence, Cell, Clinical Cancer Research, OHSU, Ponce Health Sciences University, AACR, Oregon Health & Science University, United States Air Force Scientific Advisory Board, Oregon Health and Science University Center for Women's Health, Medical director, Development of the human body, ASCO, Gastrointestinal tract, Prostate, Medical device, Medical imaging, Kineta

to the company’s immuno-oncology focused Scientific Advisory Board (SAB).

Key Points: 
  • to the company’s immuno-oncology focused Scientific Advisory Board (SAB).
  • Dr. Chalabi and Dr. Yu will join Kineta’s SAB that includes Lisa Coussens, Ph.D., Michael Curran, Ph.D. and Patricia LoRusso, D.O.
  • “We are delighted to have Dr. Chalabi and Dr. Yu join Kineta's Scientific Advisory Board,” stated Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta.
  • “These experts will greatly complement our existing SAB and guide the company as we advance clinical development of KVA12123 in patients with advanced solid tumors.”
    Myriam Chalabi, M.D.

Seer’s Proteomics Platform Named as Top 10 Innovation in 2022 by The Scientist

Retrieved on: 
Monday, December 12, 2022
Oregon Health & Science University, Seer, SEER, Health, Software, Security (finance), Genomics, Proteomics, Phenotype, Doctor of Philosophy, Biomedical Research, Knight Cancer Institute, Scientist, Research, Disease, Automation, Proteome

Seer’s proprietary-engineered nanoparticle technology is featured amongst pioneers in genomics and sequencing and is the only proteomics technology honored on the list.

Key Points: 
  • Seer’s proprietary-engineered nanoparticle technology is featured amongst pioneers in genomics and sequencing and is the only proteomics technology honored on the list.
  • Seer is a life sciences company developing transformative products that open a new gateway to the proteome.
  • Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures.
  • This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended.

NextCure Appoints Dr. Lisa M. Coussens to Scientific Advisory Board

Retrieved on: 
Thursday, October 27, 2022
Cell, University, American Association for Cancer Research, History, Associate, University of California, San Francisco, Development, Doctor of Philosophy, Society for Immunotherapy of Cancer, Nasdaq, Form 10-Q, Cancer, Forward-looking statement, Coronavirus Scientific Advisory Board (Turkey), National Center for Advancing Translational Sciences, Knight Cancer Institute, Basic research, Research, Patient, Society, Oregon Health & Science University, Leadership, American Association, Form 10-K, GLOBE, Ponce Health Sciences University, Marketing, Association, Hope, Academy, Sale, Immunotherapy, Pharmaceutical industry, Science

BELTSVILLE, Md., Oct. 27, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointment of Lisa M. Coussens, PhD, FAACR, to its Scientific Advisory Board.

Key Points: 
  • BELTSVILLE, Md., Oct. 27, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointment of Lisa M. Coussens, PhD, FAACR, to its Scientific Advisory Board.
  • We are delighted to have Dr. Coussens join our Scientific Advisory Board, where she will leverage her exceptional experience in immuno-oncology said Solomon Langermann, PhD, NextCures chief scientific officer.
  • Dr. Coussens received her PhD from the University of California, Los Angeles, and carried out her post-doctoral work at the University of California, San Francisco.
  • NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases.

NEW RESEARCH FROM NEA FINDS SHARED DECISION MAKING BENEFICIAL IN CARE OF PATIENTS WITH ECZEMA

Retrieved on: 
Wednesday, July 6, 2022
Decision-making, Patient, Caregiver, Conditional sentence, Research, Behavior, Health, JAMA Dermatology, Oregon Health and Science University Center for Women's Health, Disease, Health care, Knight Cancer Institute, NEA, Perception, OHSU Center for Health & Healing, Biostatistics, Center, Doctor of Philosophy, Seriousness, Human, Blueprint, Dermatitis, Bynea, Dermatology, MD, Multimedia, Education, Oregon Health & Science University, Health insurance, Pharmaceutical industry, Medicine, Risk management, Online shopping

NOVATO, Calif., July 6, 2022 /PRNewswire/ -- The National Eczema Association (NEA) today announced the publication of its new research revealing the importance of shared decision making between patients and healthcare providers in the treatment of eczema.

Key Points: 
  • NOVATO, Calif., July 6, 2022 /PRNewswire/ -- The National Eczema Association (NEA) today announced the publication of its new research revealing the importance of shared decision making between patients and healthcare providers in the treatment of eczema.
  • The NEA research team set out to answer these questions with a survey of its eczema patient and caregiver community.
  • Upon further analysis, they also determined that "self-reported knowledge about the causes of eczema was associated with past and future shared decision making" and that "severity of the disease was inversely associated with past shared decision making behavior."
  • These findings confirm an important role for shared decision making for improving patient satisfaction with their care.

Castle Biosciences Announces Support for OHSU’s War on Melanoma™

Retrieved on: 
Monday, June 20, 2022
Health Technology, Technology, Public Relations, Investor Relations, University, Pharmaceutical, Education, Communications, Apps, Applications, Oncology, Medical Devices, Science, Biotechnology, Other Science, Health, Research, Skin, Education, Department, Uveal melanoma, Hope, Moles, View, DecisionDx-UM, Company, Hair, Skin cancer, LinkedIn, Atopic dermatitis, Knight Cancer Institute, Health, List of life sciences, Nasdaq, Massage, Twitter, Patient, Diagnosis, OHSU, Instagram, Awareness, Pharmaceutical industry, Vaccine, Melanoma, Dermatology, Facebook

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced a new collaboration with OHSUs War on Melanoma .

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced a new collaboration with OHSUs War on Melanoma .
  • The War on Melanoma is a multi-faceted public health campaign with a focus on early detection and prevention of melanoma through various education, activism and research programs.
  • The collaboration includes support of various aspects of the War on Melanoma program, including the Start Seeing Melanoma campaign and the Skin Crew.
  • DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, myPath Melanoma, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq, TissueCypher and IDgenetix are trademarks of Castle Biosciences, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20220620005087/en/